884049-52-9

Basic information

• Product Name: Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridin]-2'(1'H)-one
• Synonyms: Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridin]-2'(1'H)-one;Spiro[piperidine-4,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one;spiro[1H-pyrrolo[2,3-b]pyridine-3,4'-piperidine]-2-one
• CAS NO: 884049-52-9
• Molecular Formula: C₁₁H₁₃N₃O
• Molecular Weight: 203.24042
• Mol File: 884049-52-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 445.6±45.0 °C
• Flash Point: 223.3±28.7 °C
• Appearance: /
• Density: 1.29±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 12.05±0.20(Predicted)
• CAS DataBase Reference: Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridin]-2'(1'H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridin]-2'(1'H)-one(884049-52-9)
• EPA Substance Registry System: Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridin]-2'(1'H)-one(884049-52-9)

Safety Data

• Hazardous Substances Data: 884049-52-9(Hazardous Substances Data)

Usage

General Description

Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridin]-2'(1'H)-one is a complex chemical compound that falls under the broad category of organic compounds. It consists of several ring structures, with key components being a piperidine ring and a pyrrolo[2,3-b]pyridine ring system. The term 'spiro' in its name indicates that these two rings are interconnected at a single atom. Due to its complex structure and unique properties, this compound might have a range of applications in various chemical reactions or industrial purposes. However, detailed information regarding its synthesis, physical and chemical properties, toxicity, and possible uses is not readily available, suggesting that it may be a less common or less well-studied compound.

Upstream product

• 883984-92-7 3,4-dihydroxyspiro[cyclopent-3-ene-1,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 59-67-6 nicotinic acid 
• 49609-84-9 2-Chloronicotinoyl chloride 
• 2942-59-8 2-chloronicotinic acid 
• 101012-32-2 2-(2-chloropyridin-3-yl)acetonitrile 
• 1315335-15-9 N-Boc-4-(2-chloropyridin-3-yl)piperidine-4-carboxamide 
• 885031-86-7 tert-butyl 2'-oxo-1',2'-dihydro-1H-spiro[piperidine-4,3'-pyrrolo[2.3-b]pyridine]-1-carboxylate 
• 1315335-16-0 2-chloro-4'-cyano-3',4',5',6'-tetrahydro-2'H-[3,4']-bipyridinyl-1'-carboxylic acid tert-butyl ester 
• 89581-84-0 2-chloro-3-(chloromethyl)pyridine 
• 42330-59-6 (2-chloropyrid-3-yl)methanol 
• 271-63-6 7-Azaindole 
• 879132-46-4 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine 
• 879132-47-5 3,3-dibromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,3-dihydro-2H-pyrrolo[2.3-b]pyridin-2-one 
• 879132-48-6 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one 

Downstream Products

• 885031-86-7 tert-butyl 2'-oxo-1',2'-dihydro-1H-spiro[piperidine-4,3'-pyrrolo[2.3-b]pyridine]-1-carboxylate 

Relevant articles and documents

Conformationally constrained ortho- Anilino diaryl ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl) -3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist

Preclinical antithrombotic efficacy and bleeding models have demonstrated that P2Y1 antagonists are efficacious as antiplatelet agents and may offer a safety advantage over P2Y12 antagonists in terms of reduced bleeding liabilities. In this article, we describe the structural modification of the tert-butyl phenoxy portion of lead compound 1 and the subsequent discovery of a novel series of conformationally constrained ortho-anilino diaryl ureas. In particular, spiropiperidine indoline-substituted diaryl ureas are described as potent, orally bioavailable small-molecule P2Y1 antagonists with improved activity in functional assays and improved oral bioavailability in rats. Homology modeling and rat PK/PD studies on benchmark compound 3l will also be presented. Compound 3l was our first P2Y1 antagonist to demonstrate a robust oral antithrombotic effect with mild bleeding liability in the rat thrombosis and hemostasis models.

Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: Development of novel spiropiperidines

Several novel spiropiperidine-based CGRP receptor antagonists have been developed that maintain good potency and have reduced potential for metabolism.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula (I): and Formula (II): (where variables R2, R4, A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.